These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 12701297)

  • 21. External radioactive reference markers in SPECT imaging of the dopamine system.
    Vines DC; Ivo BD; Ballinger JR; Ichise M
    J Nucl Med Technol; 1999 Jun; 27(2):112-6. PubMed ID: 10353107
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine-123 labeled RTI-55.
    Shaya EK; Scheffel U; Dannals RF; Ricaurte GA; Carroll FI; Wagner HN; Kuhar MJ; Wong DF
    Synapse; 1992 Feb; 10(2):169-72. PubMed ID: 1585258
    [No Abstract]   [Full Text] [Related]  

  • 23. [Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls].
    Hierholzer J; Cordes M; Schelosky L; Richter W; Schrag A; Poewe W; Schulze PE; Semmler W; Eichstädt H; Felix R
    Nuklearmedizin; 1995 Aug; 34(4):141-5. PubMed ID: 7675643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Parkinson's disease: positron emission tomographic studies.
    Martin WR
    Semin Neurol; 1989 Dec; 9(4):345-50. PubMed ID: 2701779
    [No Abstract]   [Full Text] [Related]  

  • 25. Imaging studies in movement disorders.
    Seibyl JP
    Semin Nucl Med; 2003 Apr; 33(2):105-13. PubMed ID: 12756643
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Is functional imaging useful in the clinical evaluation of Parkinson's disease?].
    Remy P
    Rev Neurol (Paris); 2003 May; 159(5 Pt 2):3S57-61. PubMed ID: 12773889
    [TBL] [Abstract][Full Text] [Related]  

  • 28. PET and SPECT studies in Parkinson's disease.
    Brooks DJ
    Baillieres Clin Neurol; 1997 Apr; 6(1):69-87. PubMed ID: 9426869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Scans without evidence of dopamine deficiency: the triumph of careful clinical assessment.
    Stoessl AJ
    Mov Disord; 2010 Apr; 25(5):529-30. PubMed ID: 20425792
    [No Abstract]   [Full Text] [Related]  

  • 30. Is iterative reconstruction an alternative to filtered backprojection in routine processing of dopamine transporter SPECT studies?
    Koch W; Hamann C; Welsch J; Pöpperl G; Radau PE; Tatsch K
    J Nucl Med; 2005 Nov; 46(11):1804-11. PubMed ID: 16269593
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET studies of the striatal dopaminergic system in Parkinson's disease (PD).
    Piccini P; Turjanski N; Brooks DJ
    J Neural Transm Suppl; 1995; 45():123-31. PubMed ID: 8748617
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical impact of correlative [123I]-FP-CIT brain imaging and neurological findings in suspect Parkinson's disease.
    Covelli EM; Brunetti A; Di Lauro A; Sullo P; Mazzarella G; Tedeschi E; Belfiore G
    Radiol Med; 2004 Oct; 108(4):417-25. PubMed ID: 15525895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dopamine transporter imaging study in parkinsonism occurring in fragile X premutation carriers.
    Ceravolo R; Antonini A; Volterrani D; Rossi C; Goldwurm S; Di Maria E; Kiferle L; Bonuccelli U; Murri L
    Neurology; 2005 Dec; 65(12):1971-3. PubMed ID: 16380622
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Controversies arising from recent FDOPA articles.
    Cumming P; Gjedde A; Reith J
    J Nucl Med; 1997 Aug; 38(8):1267-71. PubMed ID: 9255163
    [No Abstract]   [Full Text] [Related]  

  • 35. Simultaneous SPECT studies of pre- and postsynaptic dopamine binding sites in baboons.
    Dresel SH; Kung MP; Huang XF; Plössl K; Hou C; Meegalla SK; Patselas G; Mu M; Saffer JR; Kung HF
    J Nucl Med; 1999 Apr; 40(4):660-6. PubMed ID: 10210226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Imaging of dopamine transporter with Tc99m-Trodat-SPECT in movement disorders].
    Kanyó B; Argyelán M; Dibó G; Szakonyi Z; Vécsei L; Fülöp F; Láncz A; Forgács P; Pávics L
    Ideggyogy Sz; 2003 Jul; 56(7-8):231-40. PubMed ID: 12971118
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two-year follow-up in 150 consecutive cases with normal dopamine transporter imaging.
    Marshall VL; Patterson J; Hadley DM; Grosset KA; Grosset DG
    Nucl Med Commun; 2006 Dec; 27(12):933-7. PubMed ID: 17088677
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical testing of an optimized software solution for an automated, observer-independent evaluation of dopamine transporter SPECT studies.
    Koch W; Radau PE; Hamann C; Tatsch K
    J Nucl Med; 2005 Jul; 46(7):1109-18. PubMed ID: 16000279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vivo snapshots of the dopaminergic synapse in small animals.
    Nikolaus S; Beu M; Wirrwar A; Antke C; Müller HW
    Mol Psychiatry; 2005 Jun; 10(6):516-8. PubMed ID: 15920466
    [No Abstract]   [Full Text] [Related]  

  • 40. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients.
    Seibyl JP; Marek K; Sheff K; Zoghbi S; Baldwin RM; Charney DS; van Dyck CH; Innis RB
    J Nucl Med; 1998 Sep; 39(9):1500-8. PubMed ID: 9744331
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.